{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:37:43Z","timestamp":1777865863026,"version":"3.51.4"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11899-025-00753-2","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T04:23:15Z","timestamp":1751602995000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Contemporary CMML Risk Stratification and Management"],"prefix":"10.1007","volume":"20","author":[{"given":"Dahniel","family":"Sastow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjun","family":"Syal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"issue":"11","key":"753_CR1","first-page":"1200","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, J Am Soc Hematol. 2022;140(11):1200\u201328.","journal-title":"Blood, J Am Soc Hematol"},{"issue":"2","key":"753_CR2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","volume":"51","author":"JM Bennett","year":"1982","unstructured":"Bennett JM, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189\u201399.","journal-title":"Br J Haematol"},{"issue":"10","key":"753_CR3","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S0145-2126(97)00192-6","volume":"22","author":"U Germing","year":"1998","unstructured":"Germing U, et al. Problems in the classification of CMML\u2013dysplastic versus proliferative type. Leuk Res. 1998;22(10):871\u20138.","journal-title":"Leuk Res"},{"issue":"12","key":"753_CR4","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.leukres.2011.06.001","volume":"35","author":"J Neukirchen","year":"2011","unstructured":"Neukirchen J, et al. Incidence and prevalence of myelodysplastic syndromes: Data from the D\u00fcsseldorf MDS-registry. Leuk Res. 2011;35(12):1591\u20136.","journal-title":"Leuk Res"},{"key":"753_CR5","doi-asserted-by":"crossref","unstructured":"Guru Murthy GS, Dhakal I, Mehta P .Incidence and survival outcomes of chronic myelomonocytic leukemia in the United States. Leukemia Lymphoma. 2017;58(7):1648\u20131654","DOI":"10.1080\/10428194.2016.1258700"},{"key":"753_CR6","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1182\/blood-2024-197986","volume":"144","author":"DL Sastow","year":"2024","unstructured":"Sastow DL, et al. Estimating the Prevalence of Possible Undiagnosed Chronic Myelomonocytic Leukemia in the General Population: An Nhanes Analysis. Blood. 2024;144:5182.","journal-title":"Blood"},{"issue":"2","key":"753_CR7","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1016\/S2352-3026(20)30374-4","volume":"8","author":"L Pleyer","year":"2021","unstructured":"Pleyer L, et al. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. Lancet Haematol. 2021;8(2):e135\u201348.","journal-title":"Lancet Haematol"},{"issue":"22","key":"753_CR8","doi-asserted-by":"publisher","first-page":"6095","DOI":"10.1158\/1078-0432.CCR-21-0935","volume":"27","author":"AM Hunter","year":"2021","unstructured":"Hunter AM, et al. Integrated human and murine clinical study establishes clinical efficacy of ruxolitinib in chronic myelomonocytic leukemia. Clin Cancer Res. 2021;27(22):6095\u2013105.","journal-title":"Clin Cancer Res"},{"key":"753_CR9","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1182\/blood-2024-202867","volume":"144","author":"D Hiwase","year":"2024","unstructured":"Hiwase D, et al. Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine. Blood. 2024;144:1006.","journal-title":"Blood"},{"key":"753_CR10","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1182\/blood-2024-206538","volume":"144","author":"GN Mannis","year":"2024","unstructured":"Mannis GN, et al. IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results. Blood. 2024;144:1008.","journal-title":"Blood"},{"key":"753_CR11","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1182\/blood-2023-181673","volume":"142","author":"A Kishtagari","year":"2023","unstructured":"Kishtagari A, et al. Preliminary Results from a Phase 1b Dose De-Escalation Stage of Abnl-Marro 001: An International MDS\/MPN Working Group Study. Blood. 2023;142:1874.","journal-title":"Blood"},{"issue":"23","key":"753_CR12","first-page":"3618","volume":"125","author":"D Selimoglu-Buet","year":"2015","unstructured":"Selimoglu-Buet D, et al. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood, J Am Soc Hematol. 2015;125(23):3618\u201326.","journal-title":"Blood, J Am Soc Hematol"},{"issue":"9","key":"753_CR13","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/modpathol.2017.45","volume":"30","author":"JT Geyer","year":"2017","unstructured":"Geyer JT, et al. Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia. Mod Pathol. 2017;30(9):1213\u201322.","journal-title":"Mod Pathol"},{"key":"753_CR14","unstructured":"Khoury JD, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic\u00a0Neoplasms. Leukemia. 2022:36(7):1703\u20131719"},{"key":"753_CR15","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1182\/blood-2024-208890","volume":"144","author":"G Montalban-Bravo","year":"2024","unstructured":"Montalban-Bravo G, et al. Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia. Blood. 2024;144:3204.","journal-title":"Blood"},{"issue":"1","key":"753_CR16","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1038\/s41467-021-23186-w","volume":"12","author":"RM Carr","year":"2021","unstructured":"Carr RM, et al. RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nat Commun. 2021;12(1):2901.","journal-title":"Nat Commun"},{"issue":"12","key":"753_CR17","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1182\/blood.2023021199","volume":"143","author":"F Baumgartner","year":"2024","unstructured":"Baumgartner F, et al. Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022. Blood. 2024;143(12):1139\u201356.","journal-title":"Blood"},{"issue":"Supplement 1","key":"753_CR18","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1182\/blood-2024-205451","volume":"144","author":"RS Komrokji","year":"2024","unstructured":"Komrokji RS, et al. CMML Is in the Eye of the Be_Who_ Lder: Interrogating the Newly Proposed Entity of Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML): MDS or CMML? Blood. 2024;144(Supplement 1):1004\u20131004.","journal-title":"Blood"},{"issue":"Supplement 1","key":"753_CR19","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1182\/blood-2021-153475","volume":"138","author":"S Venugopal","year":"2021","unstructured":"Venugopal S, et al. Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents. Blood. 2021;138(Supplement 1):2613\u20132613.","journal-title":"Blood"},{"issue":"15","key":"753_CR20","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","volume":"121","author":"E Such","year":"2013","unstructured":"Such E, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121(15):3005\u201315.","journal-title":"Blood"},{"issue":"2","key":"753_CR21","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.critrevonc.2015.03.002","volume":"95","author":"CB Benton","year":"2015","unstructured":"Benton CB, et al. Chronic myelomonocytic leukemia: Forefront of the field in 2015. Crit Rev Oncol Hematol. 2015;95(2):222\u201342.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"753_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1756-8722-5-12","volume":"5","author":"V Gelsi-Boyer","year":"2012","unstructured":"Gelsi-Boyer V, et al. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol. 2012;5(1):12.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"753_CR23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1365-2141.2010.08381.x","volume":"151","author":"V Gelsi-Boyer","year":"2010","unstructured":"Gelsi-Boyer V, et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2010;151(4):365\u201375.","journal-title":"Br J Haematol"},{"issue":"1","key":"753_CR24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41408-024-01054-2","volume":"14","author":"D Alawieh","year":"2024","unstructured":"Alawieh D, et al. RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives. Blood Cancer J. 2024;14(1):72.","journal-title":"Blood Cancer J"},{"issue":"11","key":"753_CR25","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.3390\/biomedicines12112476","volume":"12","author":"J Di","year":"2024","unstructured":"Di J, et al. Prognostic Significance and Treatment Response Associations of Genetic Mutations in Chronic Myelomonocytic Leukemia: A Retrospective Cohort Study. Biomedicines. 2024;12(11):2476.","journal-title":"Biomedicines"},{"key":"753_CR26","doi-asserted-by":"crossref","unstructured":"Hunter AM, et al. WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State. Blood. 2019:134(Supplement_1):1717\u20131717","DOI":"10.1182\/blood-2019-131071"},{"issue":"6","key":"753_CR27","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s00277-021-04539-3","volume":"100","author":"JS Gonz\u00e1lez","year":"2021","unstructured":"Gonz\u00e1lez JS, et al. Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: a multicenter study of 280 patients. Ann Hematol. 2021;100(6):1439\u201349.","journal-title":"Ann Hematol"},{"issue":"2","key":"753_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.5","volume":"6","author":"MM Patnaik","year":"2016","unstructured":"Patnaik MM, Tefferi A. Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. Blood Cancer J. 2016;6(2): e393.","journal-title":"Blood Cancer J"},{"issue":"12","key":"753_CR29","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/ajh.23846","volume":"89","author":"EA Wassie","year":"2014","unstructured":"Wassie EA, et al. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study. Am J Hematol. 2014;89(12):1111\u20135.","journal-title":"Am J Hematol"},{"issue":"10","key":"753_CR30","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","volume":"128","author":"C Elena","year":"2016","unstructured":"Elena C, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128(10):1408\u201317.","journal-title":"Blood"},{"key":"753_CR31","doi-asserted-by":"crossref","unstructured":"Tefferi A, et al. BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia. Blood. 2025","DOI":"10.1182\/blood.2024027170"},{"issue":"6","key":"753_CR32","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ajh.27271","volume":"99","author":"MM Patnaik","year":"2024","unstructured":"Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management. Am J Hematol. 2024;99(6):1142\u201365.","journal-title":"Am J Hematol"},{"issue":"2","key":"753_CR33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.mayocp.2015.11.011","volume":"91","author":"MM Patnaik","year":"2016","unstructured":"Patnaik MM, Tefferi A. Chronic Myelomonocytic Leukemia: Focus on Clinical Practice. Mayo Clin Proc. 2016;91(2):259\u201372.","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"753_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.53","volume":"5","author":"E Padron","year":"2015","unstructured":"Padron E, et al. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015;5(7): e333.","journal-title":"Blood Cancer J"},{"issue":"3","key":"753_CR35","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood.V99.3.840","volume":"99","author":"F Onida","year":"2002","unstructured":"Onida F, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002;99(3):840\u20139.","journal-title":"Blood"},{"issue":"1","key":"753_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1365-2141.1988.tb04173.x","volume":"68","author":"A Worsley","year":"1988","unstructured":"Worsley A, et al. Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival. Br J Haematol. 1988;68(1):17\u201321.","journal-title":"Br J Haematol"},{"issue":"3","key":"753_CR37","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3324\/haematol.2010.030957","volume":"96","author":"E Such","year":"2011","unstructured":"Such E, et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica. 2011;96(3):375\u201383.","journal-title":"Haematologica"},{"issue":"19","key":"753_CR38","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","volume":"31","author":"R Itzykson","year":"2013","unstructured":"Itzykson R, et al. Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia. J Clin Oncol. 2013;31(19):2428\u201336.","journal-title":"J Clin Oncol"},{"issue":"11","key":"753_CR39","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1038\/leu.2014.125","volume":"28","author":"MM Patnaik","year":"2014","unstructured":"Patnaik MM, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia. 2014;28(11):2206\u201312.","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"753_CR40","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1182\/blood-2024-204557","volume":"144","author":"L Palomo","year":"2024","unstructured":"Palomo L, et al. Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia. Blood. 2024;144(Supplement 1):3205\u20133205.","journal-title":"Blood"},{"key":"753_CR41","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1182\/blood-2024-200104","volume":"144","author":"L Lanino","year":"2024","unstructured":"Lanino L, et al. A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML). Blood. 2024;144:1003.","journal-title":"Blood"},{"issue":"1","key":"753_CR42","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/ajh.24939","volume":"93","author":"MM Patnaik","year":"2018","unstructured":"Patnaik MM, et al. Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML. Am J Hematol. 2018;93(1):65\u201373.","journal-title":"Am J Hematol"},{"issue":"11","key":"753_CR43","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1182\/bloodadvances.2024012565","volume":"8","author":"A Bataller","year":"2024","unstructured":"Bataller A, et al. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm. Blood Adv. 2024;8(11):2695\u2013706.","journal-title":"Blood Adv"},{"key":"753_CR44","doi-asserted-by":"crossref","unstructured":"Takahashi K, et al. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood. 2013;122(16):2807\u201311; quiz 2920.","DOI":"10.1182\/blood-2013-03-491399"},{"issue":"2","key":"753_CR45","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419\u201325.","journal-title":"Blood"},{"issue":"12","key":"753_CR46","first-page":"1857","volume":"125","author":"MR Savona","year":"2015","unstructured":"Savona MR, et al. An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults. Blood, J Am Soc Hematol. 2015;125(12):1857\u201365.","journal-title":"Blood, J Am Soc Hematol"},{"issue":"12","key":"753_CR47","first-page":"1408","volume":"140","author":"M Robin","year":"2022","unstructured":"Robin M, et al. Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis. Blood, J Am Soc Hematol. 2022;140(12):1408\u201318.","journal-title":"Blood, J Am Soc Hematol"},{"key":"753_CR48","doi-asserted-by":"crossref","unstructured":"Gagelmann N, et al. Long-term survival benefit after allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Transplant Cell Ther. 2021;27(1):95. e1\u201395. e4.","DOI":"10.1016\/j.bbmt.2020.10.007"},{"issue":"11","key":"753_CR49","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41408-020-00387-y","volume":"10","author":"P Pophali","year":"2020","unstructured":"Pophali P, et al. Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. Blood Cancer J. 2020;10(11):121.","journal-title":"Blood Cancer J"},{"key":"753_CR50","doi-asserted-by":"crossref","unstructured":"Symeonidis A, et al. Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol. 2015;171(2):239\u2013246","DOI":"10.1111\/bjh.13576"},{"issue":"10","key":"753_CR51","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","volume":"20","author":"LR Silverman","year":"2002","unstructured":"Silverman LR, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429\u201340.","journal-title":"J Clin Oncol"},{"key":"753_CR52","doi-asserted-by":"crossref","unstructured":"Kantarjian H, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer: Interdisc Int J Am Cancer Soc. 2006;106(8):1794\u20131803","DOI":"10.1002\/cncr.21792"},{"key":"753_CR53","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2020-133855","volume":"136","author":"MR Savona","year":"2020","unstructured":"Savona MR, et al. Clinical efficacy and safety of oral decitabine\/cedazuridine in 133 patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Blood. 2020;136:37\u20138.","journal-title":"Blood"},{"issue":"12","key":"753_CR54","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1002\/cncr.25759","volume":"117","author":"R Costa","year":"2011","unstructured":"Costa R, et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer. 2011;117(12):2690\u20136.","journal-title":"Cancer"},{"issue":"24","key":"753_CR55","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1200\/JCO.2015.66.2510","volume":"35","author":"MA Sekeres","year":"2017","unstructured":"Sekeres MA, et al. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017;35(24):2745\u201353.","journal-title":"J Clin Oncol"},{"key":"753_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106836","volume":"116","author":"A Triguero","year":"2022","unstructured":"Triguero A, et al. Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic\/myeloproliferative neoplasms criteria. Leuk Res. 2022;116: 106836.","journal-title":"Leuk Res"},{"issue":"5","key":"753_CR57","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s10637-022-01283-x","volume":"40","author":"Y Xu","year":"2022","unstructured":"Xu Y, et al. Real-world data on efficacy and safety of azacitidine therapy in chronic myelomonocytic leukemia in China: results from a multicenter, retrospective study. Invest New Drugs. 2022;40(5):1117\u201324.","journal-title":"Invest New Drugs"},{"issue":"2","key":"753_CR58","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/leu.2017.186","volume":"32","author":"V Santini","year":"2018","unstructured":"Santini V, et al. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia. 2018;32(2):413\u20138.","journal-title":"Leukemia"},{"issue":"10","key":"753_CR59","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1200\/JCO.22.00437","volume":"41","author":"R Itzykson","year":"2023","unstructured":"Itzykson R, et al. Decitabine versus hydroxyurea for advanced proliferative chronic myelomonocytic leukemia: results of a randomized phase III trial within the EMSCO network. J Clin Oncol. 2023;41(10):1888\u201397.","journal-title":"J Clin Oncol"},{"issue":"14","key":"753_CR60","first-page":"3824","volume":"118","author":"T Braun","year":"2011","unstructured":"Braun T, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood, J Am Soc Hematol. 2011;118(14):3824\u201331.","journal-title":"Blood, J Am Soc Hematol"},{"key":"753_CR61","doi-asserted-by":"crossref","unstructured":"Aribi A, et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer: Interdisc Int J Am Cancer Soc. 2007:109(4):713\u2013717","DOI":"10.1002\/cncr.22457"},{"issue":"11","key":"753_CR62","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1182\/blood.V108.11.2676.2676","volume":"108","author":"P Wijermans","year":"2006","unstructured":"Wijermans P, et al. Efficacy of Decitabine in the Treatment of Patients with Chronic Myelomonocytic Leukemia (CMML). Blood. 2006;108(11):2676.","journal-title":"Blood"},{"issue":"7","key":"753_CR63","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/ajh.25488","volume":"94","author":"T Coston","year":"2019","unstructured":"Coston T, et al. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. Am J Hematol. 2019;94(7):767\u201379.","journal-title":"Am J Hematol"},{"key":"753_CR64","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/blood-2020-138680","volume":"136","author":"R Itzykson","year":"2020","unstructured":"Itzykson R, et al. Decitabine versus hydroxyurea for advanced proliferative CMML: results of the Emsco randomized phase 3 Dacota trial. Blood. 2020;136:53\u20134.","journal-title":"Blood"},{"issue":"7","key":"753_CR65","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"key":"753_CR66","doi-asserted-by":"crossref","unstructured":"Tremblay D, et al. Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study. Leukemia. 2024;1\u20134.","DOI":"10.1038\/s41375-024-02466-6"},{"issue":"9","key":"753_CR67","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1038\/s41375-018-0050-z","volume":"32","author":"H Than","year":"2018","unstructured":"Than H, et al. Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective. Leukemia. 2018;32(9):2049\u201354.","journal-title":"Leukemia"},{"issue":"1","key":"753_CR68","doi-asserted-by":"publisher","first-page":"10767","DOI":"10.1038\/ncomms10767","volume":"7","author":"J Merlevede","year":"2016","unstructured":"Merlevede J, et al. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nat Commun. 2016;7(1):10767.","journal-title":"Nat Commun"},{"issue":"25","key":"753_CR69","first-page":"5068","volume":"121","author":"E Padron","year":"2013","unstructured":"Padron E, et al. GM-CSF\u2013dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood, J Am Soc Hematol. 2013;121(25):5068\u201377.","journal-title":"Blood, J Am Soc Hematol"},{"issue":"Supplement 1","key":"753_CR70","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1182\/blood-2022-170144","volume":"140","author":"E Padron","year":"2022","unstructured":"Padron E, et al. Efficacy and safety of ruxolitinib for treatment of symptomatic chronic myelomonocytic leukemia (CMML): results of a multicenter phase II clinical trial. Blood. 2022;140(Supplement 1):1101\u20133.","journal-title":"Blood"},{"issue":"2","key":"753_CR71","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/ajh.24972","volume":"93","author":"R Assi","year":"2018","unstructured":"Assi R, et al. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome\/myeloproliferative neoplasms. Am J Hematol. 2018;93(2):277\u201385.","journal-title":"Am J Hematol"},{"key":"753_CR72","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer: Interdisc Int J Am Cancer Soc. 2007;109(6):1133\u20131137","DOI":"10.1002\/cncr.22508"},{"issue":"7","key":"753_CR73","first-page":"909","volume":"136","author":"MM Patnaik","year":"2020","unstructured":"Patnaik MM, et al. Phase 1 study of lenzilumab, a recombinant anti\u2013human GM-CSF antibody, for chronic myelomonocytic leukemia. Blood, J Am Soc Hematol. 2020;136(7):909\u201313.","journal-title":"Blood, J Am Soc Hematol"},{"key":"753_CR74","unstructured":"Aribi A, et al. Targeting LILRB4 (ILT3) using IO-202 in patients with chronic myelomonocytic leukemia (CMML): interim efficacy, safety, and mechanism of action data from the Phase 1b expansion cohort."},{"issue":"1","key":"753_CR75","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1186\/s12885-022-10073-w","volume":"22","author":"TK Moyo","year":"2022","unstructured":"Moyo TK, et al. The ABNL-MARRO 001 study: a phase 1\u20132 study of randomly allocated active myeloid target compound combinations in MDS\/MPN overlap syndromes. BMC Cancer. 2022;22(1):1013.","journal-title":"BMC Cancer"},{"issue":"19","key":"753_CR76","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1182\/blood.2024025648","volume":"144","author":"AM Hunter","year":"2024","unstructured":"Hunter AM, et al. Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm. Blood. 2024;144(19):1987\u201392.","journal-title":"Blood"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-025-00753-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-025-00753-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-025-00753-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T14:03:01Z","timestamp":1769090581000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-025-00753-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["753"],"URL":"https:\/\/doi.org\/10.1007\/s11899-025-00753-2","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"23 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Douglas Tremblay receives contracted research funding paid to his institution from Sobi, Sumitomo, Cogent Biosciences and Gilead and consulting fees from Sobi, AbbVie, Pharmaessentia, Geron, GSK and Cogent Biosciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"8"}}